Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Dyadic International's Debt-to-Equity or its related term are showing as below:
DYAI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -12.39 Med: 1.57 Max: 5.48
Current: -12.39
During the past 13 years, the highest Debt-to-Equity Ratio of Dyadic International was 5.48. The lowest was -12.39. And the median was 1.57.
DYAI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs DYAI: -12.39
Dyadic International (NAS:DYAI) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Dyadic International Debt-to-Equity Related Terms
Dyadic International Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Dyadic International's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DYAI vs GRDX, TVGN, KYNB: Debt-to-Equity Comparison
For the Biotechnology subindustry, Dyadic International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyadic International Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyadic International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Dyadic International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyadic International (DYAI) has a Debt-to-Equity of -12.39 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dyadic International and its competitors. According to the industry distribution chart, Dyadic International ranks #999999 out of 966 companies in the Biotechnology industry.
Is Dyadic International's Debt-to-Equity too high?
Dyadic International's current Debt-to-Equity is -12.39. Based on the distribution chart, Dyadic International ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dyadic International has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dyadic International's Debt-to-Equity compare to GRDX and TVGN?
According to the Biotechnology industry distribution chart, Dyadic International ranks #999999 out of 966 companies for Debt-to-Equity. This places Dyadic International in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dyadic International and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dyadic International's current Debt-to-Equity is -12.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyadic International stock overvalued right now?
Based on GuruFocus' analysis, Dyadic International (DYAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.74, compared to a current price of $1.47 — trading 98.6% above its estimated fair value. The current Debt-to-Equity is -12.39. Dyadic International's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Dyadic International (DYAI), the current Debt-to-Equity is -12.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dyadic International (DYAI) Overvalued in 2026?
Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued.
The current stock price of $1.47 is trading 98.6% above its estimated GF Value™ of $0.74.
GuruFocus considers Dyadic International to be Significantly Overvalued.
Key valuation signals for DYAI:
Debt-to-Equity: -12.39
GF Value™: $0.74 vs. price of $1.47 (98.6% above fair value)
No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
37GF Score
Get the complete analysis for DYAI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYAI has been successfully added to your 
